Q1 Earnings Forecast for ZVRA Issued By HC Wainwright

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a report issued on Thursday, March 13th. HC Wainwright analyst O. Livnat anticipates that the company will post earnings of ($0.23) per share for the quarter. HC Wainwright has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Zevra Therapeutics' Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.03) EPS and Q4 2025 earnings at $0.01 EPS.

A number of other equities analysts have also commented on ZVRA. JMP Securities set a $18.00 price objective on Zevra Therapeutics in a research note on Wednesday, March 12th. Canaccord Genuity Group upped their price target on Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Thursday, March 13th. Guggenheim upped their price target on Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, March 13th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Finally, Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $22.29.

Remove Ads

Zevra Therapeutics Price Performance

ZVRA stock traded down $0.38 during trading on Friday, hitting $7.97. The company had a trading volume of 319,016 shares, compared to its average volume of 574,467. The company has a fifty day moving average price of $7.92 and a two-hundred day moving average price of $8.17. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a market cap of $431.30 million, a P/E ratio of -4.05 and a beta of 1.98. Zevra Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The business had revenue of $12.00 million during the quarter, compared to the consensus estimate of $8.93 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%.

Hedge Funds Weigh In On Zevra Therapeutics

A number of large investors have recently made changes to their positions in ZVRA. Simplify Asset Management Inc. bought a new stake in Zevra Therapeutics during the third quarter valued at $833,000. Intech Investment Management LLC bought a new stake in Zevra Therapeutics during the third quarter valued at $95,000. Charles Schwab Investment Management Inc. boosted its stake in Zevra Therapeutics by 10.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 121,356 shares of the company's stock valued at $842,000 after buying an additional 11,038 shares during the period. Valence8 US LP bought a new stake in Zevra Therapeutics during the third quarter valued at $150,000. Finally, FMR LLC lifted its stake in Zevra Therapeutics by 282,687.5% during the third quarter. FMR LLC now owns 2,313,202 shares of the company's stock worth $16,054,000 after purchasing an additional 2,312,384 shares during the last quarter. 35.03% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Joshua Schafer sold 10,500 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $82,530.00. Following the completion of the transaction, the executive vice president now directly owns 29,486 shares of the company's stock, valued at $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the completion of the transaction, the chief executive officer now directly owns 222,060 shares of the company's stock, valued at approximately $1,745,391.60. This represents a 21.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 85,773 shares of company stock valued at $674,176. Corporate insiders own 2.40% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.